Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Inflammatory Bowel Disease

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease

United European Gastroenterol J.

Hanžel J, Sever N, Ferkolj I, Štabuc B, Smrekar N, Kurent T, Koželj M, Novak G, Compernolle G, Tops S, Gils A, Drobne D

doi: 10.1177/2050640619840211.

Inflammatory Bowel Disease

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Clin Gastroenterol Hepatol.

Williet N, Boschetti G, Fovet M, Di Bernado T, Claudez P, Del Tedesco E, Jarlot C, Rinaldi L, Berger A, Phelip JM, Flourie B, Nancey S, Paul S, Roblin X

doi: 10.1016/j.cgh.2016.11.023.

Inflammatory Bowel Disease

Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab

doi: 10.1097/MEG.

Inflammatory Bowel Disease

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Inflamm Bowel Dis.

Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM

doi: 10.1093/ibd/izz001.

Inflammatory Bowel Disease

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice

Biologicals.

Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T

doi: 10.1016/j.biologicals.

Inflammatory Bowel Disease

Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases

United European Gastroenterol J.

Liefferinckx C, Verstockt B, Gils A, Tops S, Van Moerkercke W, Vermeire S, Franchimont D

doi: 10.1177/2050640619841538.

Inflammatory Bowel Disease

Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland

Eur J Gastroenterol Hepatol.

Guilcher K, Fournier N, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; Swiss IBD Cohort Study

doi: 10.1097/

Inflammatory Bowel Disease

The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease

Inflamm Bowel Dis.

Kelsen JR, Conrad MA, Dawany N, Patel T, Shraim R, Merz A, Maurer K, Sullivan KE, Devoto M

doi: 10.1093/ibd/izz214.

Inflammatory Bowel Disease

Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Aliment Pharmacol Ther.

Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP; GETECCU study group

doi: 10.1111/apt.14930.

Related content

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice

Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases

Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland

The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease

Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry